Skip to main content Skip to main navigation menu Skip to site footer

Survival rate of children acute lymphoblastic leukemia at the end of therapy protocol with minimal residual disease (MRD) in Prof I G.N.G. Ngoerah General Hospital Denpasar



Abstract

Link of Video Abstract: https://youtu.be/5DFCQHg86rU

 

Background: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the survival rate of pediatric patients with ALL is currently improving, cases of relapse still occur. Minimal residual disease (MRD) status is a prognostic factor that plays an important role in recurrence of ALL patients who have been through induction therapy. Aim: To determine the survival rate in pediatric patients with ALL based on negative MRD examination is better than positive MRD at the end of therapy.

Method: A retrospective cohort study with inclusion criteria including pediatric patients aged 1 to 18 years who were diagnosed with ALL in the period of 2017-2019 at Sanglah General Hospital, Denpasar. Subject’s recruitment was initiated when the minimum number of subjects was fulfilled.

Result: From 32 research subjects, the mean age was 5.1 years, the majority obtained MRD+ results, the dominant sex was male, the average leukocyte was 28.33 thousand, most of the subjects had no mediastinal masses, and generally experienced remissions. MRD levels were found to be significantly lower in remitting patients than patients who did not achieve remission (p value <0.05). The Kaplan-Meier estimates for event-free survival on MRD status (negative versus positive) were 84.6% and 42.1% (P = 0.030).

Conclusion: There was a significant relation between MRD levels and the survival rate to achieve remission and MRD levels are significantly lower in remitting patients than patients who do not achieve remission.

Keywords: acute lymphoblastic leukemia minimal residual disease remission survival rate

References

  1. American Cancer Society (ACS). Acute lymphocytic leukemia (ALL) causes, risk factors, and prevention (no date) Acute Lymphocytic Leukemia (ALL). Tersedia di: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/causes-risks-prevention.html (Diakses pada: January 10, 2023). 2018.
  2. Starza ID, Chiaretti S, Propris MSD, Elia L, Cavalli M, De Novi LA, Soscia R. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Frontiers in Oncology. 2019. 9: 1-17. DOI: http://dx.doi.org/ 10.3389/fonc.2019.00726
  3. Hunger SP, dan Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2018. 373:16. DOI: http://dx.doi.org/ 10.1056/NEJMra1400972
  4. Yakin R, Syarif S, Tehuteru ES. Perbandingan kesintasan tiga tahun pada anak leukemia limfoblastik akut antara protokol pengobatan 2006 dan 2013. Indonesian Journal of Cancer. 2017. 11(3): 111-117. DOI: http://dx.doi.org/10.33371/ijoc.v11i3.515
  5. Larasati MCS. Perbandingan stratifikasi risiko leukemia limfoblastik akut dengan penambahan pemeriksaan imunofenotiping pada luaran kemoterapi Indonesian Protocol Acute Lymphoblastic Leukemia (LLA) 2013 Fase Induksi di RSUD Dr. Soetomo Surabaya. ADLN-Perpustakaan Universitas Airlangga. 2016.
  6. Health Quality Ontario (HQO). Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser. 2016. 16(7) :1-52. PMCID: PMC4808716
  7. Lee JW, Cho B. Prognostic factors and treatment of children acute lymphoblastic leukemia. Korean J Pediatr. 2017. 60(5): 129-137. DOI: http://dx.doi.org/ 10.3345/kjp.2017.60.5.129
  8. Rathee R, Sharma N. Acute lymphoblastic leukemia: characterization and its prognostic values. International Journal of Pharma Research & Review. 2013. 2(11): 27-36. https://www.researchgate.net/publication/260487636
  9. Kong SG, Seo JH, Jun SE, Lee BK, & Lim YT. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood research. 2014. 49(1): 29–35. DOI: http://dx.doi.org/10.5045/br.2014.49.1.29
  10. Gallegos-Arreola MP, Borjas-Gutierrez C, Zuniga-Gonzales GM, Figuera LE, Puebla-Perez AM, Garcia-Gonzales JR. Pathophysiology of acute lymphoblastic leukemia. INTECH. 2013. 3(1): 43-60. DOI: http://dx.doi.org/10.5772/54652
  11. Raetz E. Acute lymphoblastic leukemia. Leukemia & Lymphoma Society. 2014. 6-12. www.LLS.org : 800.955.4572 I
  12. Attarbaschi A, Mann G, Dworzak M, Wiesbauer P, Schrappe M, Gadner H. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. Med Pediatr Oncol. 2002. 39(6):558-565. DOI: http://dx.doi.org/10.1002/mpo.10164
  13. Vardhan R, Kotwal J, Ganguli P, Ahmed R, Sharma A, & Singh J. Mixed Phenotypic Acute Leukemia Presenting as Mediastinal Mass-2 Cases. Indian journal of hematology & blood transfusion. An official journal of Indian Society of Hematology and Blood Transfusion. 2016. 32(1): 72–77. DOI: http://dx.doi.org/10.1007/s12288-015-0611-5
  14. Jovanovska A, Martinova K, Kocheva S, Trajkova-Antevska Z, Coneska-Jovanova B, Panovska-Stavridis I, Stankovikj S, Trajkova S, Dimovski A. Clinical significance of minimal residual disease at the ed of remission induction therapy in childhood acute lymphoblastic leukemia. Journal of Medical Sciences. 2019. 7(17): 2828-2823. DOI: http://dx.doi.org/10.3889/oamjms.2019.752
  15. Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poirée M., Bordigoni P. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol. British journal of haematology. 2014. 165(3): 392–401. DOI: http://dx.doi.org/10.1111/bjh.12749.
  16. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, & Henze G. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. European journal of cancer. 2013. 49(6): 1346–1355. DOI: http://dx.doi.org/10.1016/j.ejca.2012.11.010
  17. Salim, E.J., Ariawati, K., Gustawan, I.W., Windiani, I.G.A.T., Gunawijaya, E., Hartawan, I.N.B. 2020. Diagnostic Accuracy of Bone Marrow Morphology to Determine Remission in Acute Lymphoblastic Leukemia Children: The Role of Minimal Residual Disease. Bali Medical Journal 9(1): 366-370. DOI: 10.15562/bmj.v9i1.1678
  18. Snak, E.V.P., Mahartini, N.N., Herawati, S., Mulyantari, N.K., Lestari, A.A.W. 2022. Characteristics of patients with acute lymphoblastic leukemia in 2016-2020 at Sanglah General Hospital, Bali. Bali Medical Journal 11(2): 646-650. DOI: 10.15562/bmj.v11i2.3607

How to Cite

Sanjaya, D. G. W. ., Ketut Ariawati, Putu Junara Putra, Karyana, I. P. G. ., Eka Gunawijaya, & I Made Gde Dwi Lingga Utama. (2023). Survival rate of children acute lymphoblastic leukemia at the end of therapy protocol with minimal residual disease (MRD) in Prof I G.N.G. Ngoerah General Hospital Denpasar. Bali Medical Journal, 12(3), 2415–2419. https://doi.org/10.15562/bmj.v12i3.4652
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
1

Total
1

Share

Search Panel

Dewa Gde Windu Sanjaya
Google Scholar
Pubmed
BMJ Journal

Ketut Ariawati
Google Scholar
Pubmed
BMJ Journal

Putu Junara Putra
Google Scholar
Pubmed
BMJ Journal

I Putu Gede Karyana
Google Scholar
Pubmed
BMJ Journal

Eka Gunawijaya
Google Scholar
Pubmed
BMJ Journal

I Made Gde Dwi Lingga Utama
Google Scholar
Pubmed
BMJ Journal